172 related articles for article (PubMed ID: 21819451)
21. Case Report: Biological treatment of epidermolysis bullosa acquisita: report on four cases and literature review.
Szymański K; Kowalewski C; Pietrzyk E; Woźniak K
Front Immunol; 2023; 14():1214011. PubMed ID: 37503352
[TBL] [Abstract][Full Text] [Related]
22. Current concepts in the treatment of epidermolysis bullosa acquisita.
Gürcan HM; Ahmed AR
Expert Opin Pharmacother; 2011 Jun; 12(8):1259-68. PubMed ID: 21254861
[TBL] [Abstract][Full Text] [Related]
23. IgA-mediated epidermolysis bullosa acquisita: two cases and review of the literature.
Vodegel RM; de Jong MC; Pas HH; Jonkman MF
J Am Acad Dermatol; 2002 Dec; 47(6):919-25. PubMed ID: 12451379
[TBL] [Abstract][Full Text] [Related]
24. Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulin therapy.
Asarch A; Razzaque Ahmed A
Pediatr Dermatol; 2009; 26(2):197-202. PubMed ID: 19419473
[TBL] [Abstract][Full Text] [Related]
25. Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab.
Egan CA; Brown M; White JD; Yancey KB
Clin Immunol; 2001 Nov; 101(2):146-51. PubMed ID: 11683573
[TBL] [Abstract][Full Text] [Related]
26. Epidermolysis bullosa acquisita and associated symptomatic esophageal webs.
Stewart MI; Woodley DT; Briggaman RA
Arch Dermatol; 1991 Mar; 127(3):373-7. PubMed ID: 1998368
[TBL] [Abstract][Full Text] [Related]
27. Use of intravenous immunoglobulin therapy during pregnancy in patients with pemphigus vulgaris.
Ahmed AR; Gürcan HM
J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1073-9. PubMed ID: 21143649
[TBL] [Abstract][Full Text] [Related]
28. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris.
Engineer L; Bhol KC; Ahmed AR
J Am Acad Dermatol; 2000 Dec; 43(6):1049-57. PubMed ID: 11100022
[TBL] [Abstract][Full Text] [Related]
29. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases.
Harman KE; Black MM
Br J Dermatol; 1999 May; 140(5):865-74. PubMed ID: 10354024
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of high-dose intravenous human immunoglobulins treatment for refractory recurrent pericarditis.
Moretti M; Buiatti A; Merlo M; Massa L; Fabris E; Pinamonti B; Sinagra G
Am J Cardiol; 2013 Nov; 112(9):1493-8. PubMed ID: 23972350
[TBL] [Abstract][Full Text] [Related]
31. [Multifocal motor neuropathy: a retrospective study of the response to high-dose intravenous immunoglobulin (IVIg) and current perspectives for diagnosis and treatment].
Léger JM; Viala K; Maisonobe T; Bouche P
Bull Acad Natl Med; 2007 Oct; 191(7):1395-407; discussion 1407-9. PubMed ID: 18447061
[TBL] [Abstract][Full Text] [Related]
32. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.
Letko E; Miserocchi E; Daoud YJ; Christen W; Foster CS; Ahmed AR
Clin Immunol; 2004 Jun; 111(3):303-10. PubMed ID: 15183151
[TBL] [Abstract][Full Text] [Related]
33. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients.
Cherin P; Piette JC; Wechsler B; Bletry O; Ziza JM; Laraki R; Godeau P; Herson S
J Rheumatol; 1994 Jun; 21(6):1092-7. PubMed ID: 7932419
[TBL] [Abstract][Full Text] [Related]
34. Epidermolysis bullosa acquisita in childhood.
Callot-Mellot C; Bodemer C; Caux F; Bourgault-Villada I; Fraitag S; Goudié G; Heller M; de Prost Y; Prost C
Arch Dermatol; 1997 Sep; 133(9):1122-6. PubMed ID: 9301589
[TBL] [Abstract][Full Text] [Related]
35. Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy.
Gordon KB; Chan LS; Woodley DT
Br J Dermatol; 1997 Mar; 136(3):415-20. PubMed ID: 9115929
[TBL] [Abstract][Full Text] [Related]
36. Passive transfer of autoantibodies from a patient with mutilating epidermolysis bullosa acquisita induces specific alterations in the skin of neonatal mice.
Borradori L; Caldwell JB; Briggaman RA; Burr CE; Gammon WR; James WD; Yancey KB
Arch Dermatol; 1995 May; 131(5):590-5. PubMed ID: 7741548
[TBL] [Abstract][Full Text] [Related]
37. The role of IVIg treatment in severe pemphigus vulgaris.
Baum S; Scope A; Barzilai A; Azizi E; Trau H
J Eur Acad Dermatol Venereol; 2006 May; 20(5):548-52. PubMed ID: 16684282
[TBL] [Abstract][Full Text] [Related]
38. Short and long-term effect of IVIg in demyelinating neuropathy associated with MGUS, experience of a monocentric study.
Théaudin M; Lozeron P; Lacroix C; Chrétien P; Ducot B; Denier C; Adams D
Rev Neurol (Paris); 2011 Dec; 167(12):897-904. PubMed ID: 22023823
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins.
Mohr C; Sunderkötter C; Hildebrand A; Biel K; Rütter A; Rütter GH; Luger TA; Kolde G
Br J Dermatol; 1995 May; 132(5):824-6. PubMed ID: 7772494
[TBL] [Abstract][Full Text] [Related]
40. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid.
Shimanovich I; Mihai S; Oostingh GJ; Ilenchuk TT; Bröcker EB; Opdenakker G; Zillikens D; Sitaru C
J Pathol; 2004 Dec; 204(5):519-27. PubMed ID: 15538734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
